IL2, a well-known T-cell growth factor approved for the treatment of metastatic melanoma and renal cell carcinoma, promotes the in situ recruitment and activation of cytotoxic immunocytes and switches the immunosuppressive TME toward antitumor immune responses [14,28]. Here, TBXT is linked to hereditary clear cell renal cell carcinoma.